Cite
Phase I Study of Taminadenant (PBF509/NIR178), an Adenosine 2A Receptor Antagonist, with or without Spartalizumab (PDR001), in Patients with Advanced Non-Small Cell Lung Cancer.
MLA
Chiappori, Alberto A., et al. “Phase I Study of Taminadenant (PBF509/NIR178), an Adenosine 2A Receptor Antagonist, with or without Spartalizumab (PDR001), in Patients with Advanced Non-Small Cell Lung Cancer.” Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, vol. 28, no. 11, June 2022, pp. 2313–20. EBSCOhost, https://doi.org/10.1158/1078-0432.CCR-21-2742.
APA
Chiappori, A. A., Creelan, B., Tanvetyanon, T., Gray, J. E., Haura, E. B., Thapa, R., Barlow, M. L., Chen, Z., Chen, D. T., Beg, A. A., Boyle, T. A., Castro, J., Morgan, L., Morris, E., Aregay, M., Hurtado, F. K., Manenti, L., & Antonia, S. (2022). Phase I Study of Taminadenant (PBF509/NIR178), an Adenosine 2A Receptor Antagonist, with or without Spartalizumab (PDR001), in Patients with Advanced Non-Small Cell Lung Cancer. Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, 28(11), 2313–2320. https://doi.org/10.1158/1078-0432.CCR-21-2742
Chicago
Chiappori, Alberto A, Ben Creelan, Tawee Tanvetyanon, Jhanelle E Gray, Eric B Haura, Ram Thapa, Margaret L Barlow, et al. 2022. “Phase I Study of Taminadenant (PBF509/NIR178), an Adenosine 2A Receptor Antagonist, with or without Spartalizumab (PDR001), in Patients with Advanced Non-Small Cell Lung Cancer.” Clinical Cancer Research : An Official Journal of the American Association for Cancer Research 28 (11): 2313–20. doi:10.1158/1078-0432.CCR-21-2742.